Heartgard Plus

Verify with FDA CVM →

138 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
138
Total Reports
3
Deaths Reported
220.0%
Death Rate

Active Ingredients

Heartgard Plus

Administration Routes

OralUnknown

Species Affected

Dog 138

Most Affected Breeds

Retriever - Labrador 16
Crossbred Canine/dog 11
Chihuahua 10
Terrier - Bull - American Pit 8
Retriever - Golden 7
Shepherd Dog - German 6
Beagle 5
Terrier (unspecified) 4
Shepherd Dog - Australian 3
Shepherd Dog - Belgian Malinois 3

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 83
Seizure NOS 8
Polyuria 7
Urinary incontinence 6
Lethargy (see also Central nervous system depression in Neurological) 5
Decreased appetite 4
Vomiting 4
Twitching 4
Emesis (multiple) 4
Diarrhoea 4
Urinary tract infection 4
Ataxia 3

Outcome Breakdown

Ongoing
104 (75.4%)
Outcome Unknown
19 (13.8%)
Recovered/Normal
12 (8.7%)
Euthanized
2 (1.4%)
Died
1 (0.7%)

Data Summary

Metric Value
Total adverse event reports 138
Reports involving death 3
Case-fatality rate (reported events) 220.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Heartgard Plus Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 138 adverse event reports referencing Heartgard Plus, including 3 reports in which the animal died — a 220.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Heartgard Plus. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Heartgard Plus reports are Dog (138 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (16), Crossbred Canine/dog (11), Chihuahua (10) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Heartgard Plus are Lack of efficacy (endoparasite) - heartworm (83), Seizure NOS (8), Polyuria (7), Urinary incontinence (6). Of the 138 reports with a coded outcome, Ongoing is the leading category at 75.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Heartgard Plus.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial